Electronic Supplementary Information for

Cytotoxic evaluation and DNA interaction of Ru^{II}-bipy complexes containing coumarin-based ligands

Patrícia S. V. B. de Almeida^a, Henrique Jefferson de Arruda^a, Gleyton Leonel S. Sousa^a, Felipe Vitório Ribeiro^a, José Aleixo de Azevedo-França^b, Larissa A. Ferreira^a, Guilherme P. Guedes^c, Heveline Silva^d, Arthur E. Kummerle^a and Amanda P. Neves^a*

^aInstituto de Química, Universidade Federal Rural do Rio de Janeiro, BR 465 Km 7, 23890-000, Seropédica, RJ, Brazil. E-mail: amandanevess@ufrrj.br

^bInstituto de Ciências Exatas, Departamento de Química, Universidade Federal de Juiz de Fora, MG, Brazil.

^cInstituto de Química, Universidade Federal Fluminense, Niterói, RJ, Brazil.

^dInstituto de Ciências Exatas, Departamento de Química, Universidade Federal de Minas Gerais, MG, Brazil.

SUMMARY

I. Etł	nyl 3-(6-methyl-2-oxo-2 <i>H</i> -chromen-3-yl)-3-oxopropanoate (HL1)3
II. Etł	nyl 3-(7-(diethylamino)-2-oxo-2 <i>H</i> -chromen-3-yl)-3-oxopropanoate (HL2)6
III.	Ethyl 3-(8-methoxy-2-oxo-2 <i>H</i> -chromen-3-yl)-3-oxopropanoate (HL3)7
IV.	cis-bis(2,2'-bipyridyl)-[3-(6-(methyl)-2-oxo-2H-chromen-3-yl)-3-
oxoet	hylpropanoate]-ruthenium (II) hexafluorophosphate (1)11
V. cis	-bis(2,2'-bipyridyl)-[3-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-3
oxoet	hylpropanoate] ruthenium (II) hexafluorophosphate (2)14
VI.	cis-bis(2,2'-bipyridyl)-[3-(8-(methoxy)-2-oxo-2H-chromen-3-yl)-3-
oxoet	hylpropanoate] ruthenium (II) hexafluorophosphate (3)16
VII.	X-Ray diffraction analysis
VIII.	Biological studies



Figure S2: UV-Vis spectrum of HL1 in phosphate buffer at 5×10^{-5} M.

Wavelenght (nm)

500

600

400

363

0.25

0.00

300



ure S3: ¹H NMR spectrum of HL1 (A) and COSY spectrum (B). Solvent: CDCl₃.



Figure S4: MS/ESI mass spectrum of HL1.



II. Ethyl 3-(7-(diethylamino)-2-oxo-2*H*-chromen-3-yl)-3-oxopropanoate (HL2)





Figure S6: UV-Vis spectrum of HL2 in phosphate buffer at 2×10^{-5} M.



Figure S7: ¹H NMR spectrum of HL2 (A). Solvent: CDCl₃.



Figure S8: MS/ESI mass spectrum of HL2.

III. Ethyl 3-(8-methoxy-2-oxo-2*H*-chromen-3-yl)-3-oxopropanoate (HL3)







Figure S10: UV-Vis spectrum of HL3 in phosphate buffer at 6×10^{-5} M.



Figure S11: ¹H NMR spectrum of HL3 (A) and COSY spectrum (B). Solvent: CDCl₃.



Figure S12: MS/ESI mass spectrum of HL3.

IV. cis-bis(2,2'-bipyridyl)-[3-(6-(methyl)-2-oxo-2H-chromen-3-yl)-3-oxoethylpropanoate]ruthenium (II) hexafluorophosphate (1)



Figure S13: IR spectrum of 1.



Figure S14: UV-Vis spectrum of 1 in phosphate buffer at 9×10^{-6} M.



Figure S15: UV-Vis spectrum of 1 recorded over time within 24h, in phosphate buffer at 1.0 x 10^{-5} M.



Figure S16: ¹H NMR spectra of 1 (A). Expanded region from 6.9 to 9.3 ppm (B). Solvent: CDCl₃.



Figure S17: COSY spectra of 1 (C). Expanded region from 6.5 to 9.5 ppm (D). Solvent: CDCl₃.

V. *cis*-bis(2,2'-bipyridyl)-[3-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-3 oxoethylpropanoate] ruthenium (II) hexafluorophosphate (2)







Figure S19: UV-Vis spectrum of the complex 2 in phosphate buffer at 2×10^{-5} M.



Figure S20: UV-Vis spectrum of **2** recorded over time within 24h, in phosphate buffer at 1.0 x 10^{-5} M.



Figure S21: ¹H NMR spectra of 1 (A). Expanded region from 6.0 to 9.5 ppm (B). Solvent: CDCl₃



Figure S22: COSY spectra of 2 (C). Expanded region from 6.5 to 9.5 ppm (D). Solvent: $CDCl_3$.

VI. *cis*-bis(2,2'-bipyridyl)-[3-(8-(methoxy)-2-oxo-2*H*-chromen-3-yl)-3-oxoethylpropanoate] ruthenium (II) hexafluorophosphate **(3)**



Figure S23: IR spectrum of 3.



Figure S24: UV-Vis spectrum of 3 in phosphate buffer at 1.5×10^{-5} M.



Figure S25: UV-Vis spectrum of **3** recorded over time within 24h, in phosphate buffer at 1.2 x 10^{-5} M.



Figure S26: ¹H NMR spectra of **3** (**A**). Expanded region from 6.5 to 9.5 ppm (**B**). Solvent: CDCl₃



Figure S27: COSY spectra of 3 (C). Expanded region from 7.0 to 9.5 ppm (D). Solvent: CDC13.

VII. X-Ray diffraction analysis

Chemical formula	$C_{38}H_{36}F_6N_5O_5PRu$
Formula weigh	888.76
Crystal system	monoclinic
a/Å	28.3360(12)
b/Å	10.5670(3)
c/Å	26.8770(9)
α/°	90
β/°	110.5490(10)
γ/°	90
Unit cell volume (Å ³)	7535.6(5)
Т (К)	273(2)
Space group	C 2/c
Formula units per cell, Z	8
Radiation type	ΜοΚα
Absorption coefficient (mm ⁻¹)	0.539
Reflections measured	41132
Independents reflections	6637
R _{int}	0.0521
Final R_1 values ($I > 2\sigma(I)$)	0.0361
Final $wR(F^2)$ values ($I > 2\sigma(I)$)	0.0773
Final R_1 values (all data)	0.0522
Final $wR(F^2)$ values (all data)	0.0849
Goodness of (GOF) fit F ²	1.046
CCDC deposition	2076893

 Table S1: Summary of crystal structure, data collection and refinement for complex 2.

Table S2: Hydrogen-bond geometry (Å, °) for 2.

D —H…A	<i>D</i> —Н	Н…А	D ····A	D —H…A
C35—H35F5i	0.93	2.99	3.306(4)	101.4
C38—H38O4	0.93	2.61	3.149(4)	117.8
C28—H28F4	0.93	2.51	3.140(4)	125.5

Symmetry code: (i) -x+1, -y+2, -z+1.

VIII. Biological studies



Figure S28. Absorption spectra of the ct-DNA in the presence of methanol in different proportions. Methanol = 0, 0.6, 1.2, 2.4, 3.6, 4.8 and 6.0%. ct-DNA at a concentration of 120 μ M in Tris-HCl buffer (pH 7.4).



Figure S29. Circular dichroism of DNA at a concentration of 120 μ M in Tris-HCl buffer (pH 7.4), in the presence of increasing methanol proportions (0 to 6 %).



Figure S30. Absorption spectra of HL1 at 30 μ M in Tris-HCl buffer (pH 7.4) in the presence of ct-DNA in different concentrations. ct-DNA = 0, 10, 20, 40, 60, 80, 100 and 120 μ M. λ (Kb) = 327 nm.



Figure S31. Absorption spectra of HL2 at 30 μ M in Tris-HCl buffer (pH 7.4) in the presence of ct-DNA in different concentrations. ct-DNA = 0, 10, 20, 40, 60, 80, 100 and 120 μ M. λ (Kb) = 453 nm.



Figure S32. Absorption spectra of HL3 at 30 μ M in Tris-HCl buffer (pH 7.4) in the presence of ct-DNA in different concentrations. ct-DNA = 0, 10, 20, 40, 60, 80, 100 and 120 μ M. λ (Kb) = 303 nm.



Figure S33. Absorption spectra of *cis*-[Ru(bipy)₂Cl₂] at 30 μ M in Tris-HCl buffer (pH 7.4) in the presence of ct-DNA in different concentrations. ct-DNA = 0, 10, 20, 40, 60, 80, 100 and 120 μ M. λ (Kb) = 490 nm.



Figure S34. Absorption spectra of complex 1 at 30 μ M in Tris-HCl buffer (pH 7.4) in the presence of ct-DNA in different concentrations. CtDNA = 0, 10, 20, 40, 60, 80, 100 and 120 μ M. λ (Kb) = 487 nm.



Figure S35. Absorption spectra of complex 2 at 30 μ M in Tris-HCl buffer (pH 7.4) in the presence of ct-DNA in different concentrations. CtDNA = 0, 10, 20, 40, 60, 80, 100 and 120 μ M. λ (Kb) = 450 nm.



Figure S36. Absorption spectra of complex 3 at 30 μ M in Tris-HCl buffer (pH 7.4) in the presence of ct-DNA in different concentrations. CtDNA = 0, 10, 20, 40, 60, 80, 100 and 120 μ M. λ (Kb) = 490 nm.



Figure S37. Circular dichroism of DNA at a concentration of 300 μ M in Tris-HCl buffer (pH 7.4), in the presence of increasing concentrations of complex 1 (10, 20, 40, 60, 80 and 100 μ M).



Figure S38. Circular dichroism of DNA at a concentration of 300 μ M in Tris-HCl buffer (pH 7.4), in the presence of increasing concentrations of complex **3** (10, 20, 40, 60, 80 and 100 μ M).



Figure S39. Circular dichroism spectra of the ct-DNA at different concentrations ([DNA] = 10, 60 and 100 μ M) in the presence of compound **2** at 50 μ M in Tris-HCl buffer (pH 7.4).



Figure S40. Fluorescence emission spectra of **HL2** and **2**, obtained at 50 μ M (λ ex = 440 nm) in Tris-HCl buffer (pH 7.4) and recorded in an Edinburgh FLS980 spectrofluorometer.



Figure S41. Emission quenching curves of EtdBr-DNA by complex 1 ([EtBr] = 10 μ M, [DNA] = 100 μ M, [Complex] = 0–100 μ M.



Figure S42. Emission quenching curves of EtdBr-DNA by complex 2 ([EtBr] = 10 μ M, [DNA] = 100 μ M, [Complex] = 0–100 μ M.



Figure S43. Emission quenching curves of EtdBr-DNA by complex **3** ([EtBr] = 10 μ M, [DNA] = 100 μ M, [Complex] = 0–100 μ M.



Figure S44. Redocking for target 1Z3F, available in PDB, Structure of ellipticine in complex with a 6-bp DNA, RMSD = 0.45.

COMPOUNDS	SCORE	
1	67.28	
2	68.62	
3	64.88	
Ellipticine	75.45 (RMSD 0.45)	

Table S3: Molecular docking results for 1Z3F (PDB).